OptimizeRx (NASDAQ:OPRX - Get Free Report) had its target price decreased by equities researchers at B. Riley from $17.00 to $13.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm currently has a "buy" rating on the stock. B. Riley's price objective points to a potential upside of 163.16% from the company's current price.
A number of other research firms have also weighed in on OPRX. JMP Securities reduced their target price on OptimizeRx from $16.00 to $8.00 and set a "market outperform" rating for the company in a report on Thursday, November 14th. Stifel Nicolaus reduced their price objective on shares of OptimizeRx from $13.00 to $8.00 and set a "buy" rating for the company in a research note on Thursday, November 14th. Barclays decreased their target price on shares of OptimizeRx from $11.00 to $5.00 and set an "equal weight" rating on the stock in a report on Thursday, November 14th. William Blair reissued an "outperform" rating on shares of OptimizeRx in a report on Thursday, November 14th. Finally, Royal Bank of Canada reduced their price target on shares of OptimizeRx from $14.00 to $7.00 and set an "outperform" rating for the company in a research report on Thursday, November 14th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $9.19.
Check Out Our Latest Research Report on OptimizeRx
OptimizeRx Stock Performance
Shares of OPRX stock traded up $0.11 on Tuesday, hitting $4.94. 204,473 shares of the stock were exchanged, compared to its average volume of 165,176. The firm's 50 day moving average is $5.34 and its two-hundred day moving average is $7.73. OptimizeRx has a one year low of $3.78 and a one year high of $16.65. The firm has a market capitalization of $91.00 million, a PE ratio of -3.71 and a beta of 1.34. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 0.29.
Insider Transactions at OptimizeRx
In other news, CEO William J. Febbo acquired 20,000 shares of the firm's stock in a transaction that occurred on Thursday, December 12th. The shares were bought at an average cost of $5.01 per share, with a total value of $100,200.00. Following the acquisition, the chief executive officer now owns 601,253 shares in the company, valued at approximately $3,012,277.53. This represents a 3.44 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 6.10% of the company's stock.
Institutional Trading of OptimizeRx
Hedge funds and other institutional investors have recently bought and sold shares of the company. Janney Montgomery Scott LLC bought a new stake in shares of OptimizeRx in the 3rd quarter worth approximately $810,000. Rice Hall James & Associates LLC raised its position in OptimizeRx by 24.0% in the 3rd quarter. Rice Hall James & Associates LLC now owns 615,441 shares of the company's stock worth $4,751,000 after purchasing an additional 119,306 shares during the period. Renaissance Technologies LLC lifted its stake in OptimizeRx by 101.8% in the second quarter. Renaissance Technologies LLC now owns 142,146 shares of the company's stock worth $1,421,000 after purchasing an additional 71,700 shares during the last quarter. First Light Asset Management LLC boosted its position in OptimizeRx by 5.1% during the second quarter. First Light Asset Management LLC now owns 1,826,961 shares of the company's stock valued at $18,270,000 after buying an additional 89,377 shares during the period. Finally, Quest Partners LLC grew its stake in shares of OptimizeRx by 15,965.6% during the third quarter. Quest Partners LLC now owns 9,800 shares of the company's stock valued at $76,000 after buying an additional 9,739 shares during the last quarter. Hedge funds and other institutional investors own 76.47% of the company's stock.
About OptimizeRx
(
Get Free Report)
OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.
Read More
Before you consider OptimizeRx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OptimizeRx wasn't on the list.
While OptimizeRx currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
